The historical rank and industry rank for Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity or its related term are showing as below:
SHPMF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.54 Med: 14.32 Max: 16.86
Current: 10.63
During the past 13 years, Shanghai Pharmaceuticals Holding Co's highest Return-on-Tangible-Equity was 16.86%. The lowest was 7.54%. And the median was 14.32%.
SHPMF's Return-on-Tangible-Equity is ranked better than 59.46% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs SHPMF: 10.63
Shanghai Pharmaceuticals Holding Co (OTCPK:SHPMF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai Pharmaceuticals Holding Co Return-on-Tangible-Equity Related Terms
Shanghai Pharmaceuticals Holding Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co Return-on-Tangible-Equity Chart
SHPMF vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.39% mean?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Return-on-Tangible-Equity of 10.39% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. This is 27% below median its historical median of 14.32. Over the past decade, Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity has ranged from 7.54 to 16.86. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #45 out of 111 companies in the Medical Distribution industry, placing it in the top 40.5%.
Is Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity too high?
Shanghai Pharmaceuticals Holding Co's current Return-on-Tangible-Equity of 10.39% is 27% below median its 10-year median of 14.32. Over the past 10 years, this metric has ranged from a low of 7.54 to a high of 16.86. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Shanghai Pharmaceuticals Holding Co's value of 10.39% is 17.9% above this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #45 out of 111 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #45 out of 111 companies for Return-on-Tangible-Equity. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Shanghai Pharmaceuticals Holding Co's value of 10.39% is 17.9% above this benchmark. Historically, Shanghai Pharmaceuticals Holding Co's own Return-on-Tangible-Equity has ranged from 7.54 to 16.86 over the past decade. While the company's 10-year median is 14.32 vs. the industry median of 8.81, Shanghai Pharmaceuticals Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current Return-on-Tangible-Equity of 10.39% is 17.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current Return-on-Tangible-Equity is 10.39%, which is 27% below median its own 10-year median of 14.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Return-on-Tangible-Equity of 10.39%. The stock's GF Value™ is $1.81, compared to a current price of $1.46 — trading 19.3% below its estimated fair value. The current Return-on-Tangible-Equity is 10.39%, which is 27% below median its 10-year median of 14.32 and 17.9% above the Medical Distribution industry median of 8.81. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Return-on-Tangible-Equity is 10.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 19.3% below its estimated GF Value™ of $1.81.
Key valuation signals for SHPMF:
Return-on-Tangible-Equity: 10.39% (27% below median its 10-year median of 14.32)
GF Value™: $1.81 vs. price of $1.46 (19.3% below fair value)
Industry Position: 17.9% above the Medical Distribution median (#45 of 111)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Business Description
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
77GF Score
Get the complete analysis for SHPMF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
